OncoMatch/Clinical Trials/NCT06937866
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Is NCT06937866 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Zanzalintinib and Etoposide Capsule for germ cell tumor.
Treatment: Zanzalintinib · Etoposide Capsule — This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Testicular Germ Cell Tumor
Disease stage
Required: Stage IV
Metastatic disease required
incurable, refractory or relapsed metastatic germ cell tumor
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: cisplatin-based combination chemotherapy (cisplatin) — initial
Must have received initial cisplatin-based combination chemotherapy AND demonstrated progression following at least one salvage regimen for advanced germ-cell neoplasm and now considered incurable with standard therapies, including further chemotherapy or surgery.
Must have received: salvage chemotherapy — advanced
demonstrated progression following at least one salvage regimen for advanced germ-cell neoplasm
Must have received: high-dose chemotherapy and peripheral blood stem cell transplant — salvage
Completed salvage treatment with HDCT and PBSCT for 2 tandem cycles per Institutional Guidelines
Cannot have received: zanzalintinib (zanzalintinib)
Prior treatment with zanzalintinib
Cannot have received: etoposide (if prior hypersensitivity not recovered with supportive care) (etoposide)
Exception: if prior hypersensitivity not recovered with supportive care
Prior hypersensitivity to etoposide which did not recover with supportive care
Lab requirements
Blood counts
Hemoglobin ≥ 9g/dL; WBC ≥ 2500/µL; Absolute neutrophil count ≥ 1500/mm3; Platelet count ≥ 100,000/mm3
Kidney function
Calculated creatinine clearance ≥ 50 mL/min (≥ 0.67 mL/sec) using the Cockcroft Gault equation; Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol) creatinine.
Liver function
Total bilirubin ≤ 1.5 X ULN except patients with documented Gilbert's syndrome (≤ 3 X ULN); ALT, AST, ALP ≤3 X ULN; for patients with hepatic metastases, ALT and AST ≤ 5 X ULN. For subjects with documented bone metastasis ALP ≤ 5 X ULN.
Cardiac function
Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 480 ms per electrocardiogram (ECG) within 14 days of study registration.
Adequate laboratory values obtained within 14 days prior to registration for protocol therapy and as defined below: ... Hemoglobin ≥ 9g/dL ... WBC ≥ 2500/µL ... Absolute neutrophil count ≥ 1500/mm3 ... Platelet count ≥ 100,000/mm3 ... Total bilirubin ≤ 1.5 X ULN except patients with documented Gilbert's syndrome (≤ 3 X ULN) ... ALT, AST, ALP ≤3 X ULN; for patients with hepatic metastases, ALT and AST ≤ 5 X ULN. For subjects with documented bone metastasis ALP ≤ 5 X ULN. ... Calculated creatinine clearance ≥ 50 mL/min (≥ 0.67 mL/sec) using the Cockcroft Gault equation. ... Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol) creatinine. ... Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 480 ms per electrocardiogram (ECG) within 14 days of study registration.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center · Indianapolis, Indiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06937866 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior zanzalintinib, etoposide (if prior hypersensitivity not recovered with supportive care) disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages